{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.6","upperLimit":"10.2","value":"7.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Time from date of first dose of study treatment to the date of first documented evidence of progressive disease, death or date of censoring for the subjects not progressed/died. The censoring date was the last adequate tumor assessment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg\n\nIbrutinib\n\nCarfilzomib\n\nDexamethasone","id":"OG000","title":"All RP2D (840 mg)"}],"paramType":"MEDIAN","populationDescription":"Please note that the analysis only includes participants who achieved the best response of complete response or partial response from the All RP2D population (per protocol).","reportingStatus":"POSTED","timeFrame":"Up to 4 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}